Independent scientific consulting

Senior scientists.
Direct engagement.

We help testing labs and manufacturers prove their products are safe and made right — meeting the strict standards regulators demand, and fixing things fast when an inspection or a test goes wrong. We work across cannabis, hemp, food, pharmaceuticals, and dietary supplements.

EmergencyFacing an FDA 483, a stop order, or an ISO 17025 accreditation suspension? We scope a response within 24–48 hours.

Get senior help →
What we do: we help testing labs and manufacturers build quality systems, fix problems fast, and get ready for inspection — so their products are trusted by regulators.

Why this firm exists

Most consulting firms grow by hiring junior staff under senior partners. The partners sell the engagement; the juniors execute it. By the time the work lands on a bench, the senior name that won the deal is two or three calls removed.

Intrepid Scientific exists to invert that model.

We are four principals — three PhDs and a pharmaceutical-trained quality professional — each with an established consulting practice and a public reputation in our fields. We chose each other after years of collaborating on shared engagements and expert-witness matters. We are now consolidating that work into a single firm so clients can engage four senior specialists under one contract, with one point of accountability, and no junior backfill.

The names on the wall deliver the work. Andrew runs the project. Kate, Julie, and Tess work the bench, the audit, or the deposition themselves. There is no junior associate inserted after the sale.

Cofounders

Vetted alignment, not assembled team. We picked each other.

Andrew Samann

Andrew Samann

B.S. Biochemistry (U-M)

GMP, regulatory, QMS. Former ICH Q7 lead auditor for SGS North America. Led ASTM D37.02 QMS Subcommittee for Cannabis. 100+ engagements across NA, SA, EU.

Kate Evans, PhD

Kate Evans, PhD

Ph.D., analytical chemistry + microbiology

ANAB and A2LA lead assessor (ISO/IEC 17025). Technical Contact, ASTM D8493-23. Pharma analysis + cGMP.

Tess Eidem, PhD

Tess Eidem, PhD

Ph.D., Microbiology · food-safety certified (PCQI)

Cannabis bioaerosols, environmental monitoring, microbiology QC. Senior Research Associate, CU Boulder.

Julie Kowalski, PhD

Julie Kowalski, PhD

Ph.D., Analytical Chemistry

A2LA ISO 17025 lead assessor. Co-Chair, AOAC CASP Pesticide Think Tank. Past President NACRW. GC/LC method development and validation.

One pathway, every regulator: DEA Schedule III, a new state market, the FDA, and EU export all reduce to the same two moves — set your specifications and risks, then control and verify.

Federal cannabis Schedule III

Preparing for Schedule III

Rescheduling moved state-medical marijuana to Schedule III, and the DEA has begun on-site inspections of registered operators — asking for SOPs, security plans, training records, and process narratives. Readiness now means documented, risk-based compliance.

Our free Risk Assessment Worksheet walks the method end to end: set your specifications (CQAs/CSAs), run an ICH Q9 risk assessment, prioritize controls, and record verification — the same pathway whether the regulator is the DEA, a new state market, the FDA, or the EU.

Talk to us

Send a note. Tell us a little about what you’re working on. We reply directly, from a senior member of the firm.